Back to all studies
TerminatedNCT05359081

Safety study of SEP-363856 in schizophrenia

This study was terminated in Japan. It is testing SEP-363856 for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether SEP-363856 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive SEP-363856, attend study visits with the research team. The registry lists locations in Japan.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: May 16, 2022
Recruitment status
Terminated
Enrollment listed in the registry
68
Sponsor
Sumitomo Pharma Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan
Age range
From 18 Years to 65 Years
Official registry ID
NCT05359081
Official title
A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT05359081. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Japan · 51 sites
  • Hotei Hospital
    Konan-shi, Aichi-ken
    Site status: Not listed — confirm with the team
  • Heart Care Clinic Omachi
    Akita, Akita
    Site status: Not listed — confirm with the team
  • Seinan Hospital
    Hachinohe-shi, Aomori
    Site status: Not listed — confirm with the team
  • Ishigooka Hospital
    Chiba, Chiba
    Site status: Not listed — confirm with the team
  • Kohnodai Hospital National Center for Global Health and Medicine
    Ichikawa-shi, Chiba
    Site status: Not listed — confirm with the team
  • Fukui Hospital
    Fukui-shi, Fukui
    Site status: Not listed — confirm with the team
  • Ai Sakura Clinic
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Inokuchi Noma Hospital
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Kuramitsu Hospital
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Medical corporation Shinseikai Kaku Mental Clinic
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Mental Clinic Sakurazaka
    Fukuoka, Fukuoka
    Site status: Not listed — confirm with the team
  • Shiranui Hospital
    Omuta-shi, Fukuoka
    Site status: Not listed — confirm with the team
  • Takeda General Hospital
    Aizuwakamatsu-shi, Fukushima
    Site status: Not listed — confirm with the team
  • Medical Corporation Kishikai Kishi Hospital
    Kiryu-shi, Gunma
    Site status: Not listed — confirm with the team
  • Hayakawa Clinic
    Kure-shi, Hiroshima
    Site status: Not listed — confirm with the team
  • NHO Kure Medical Center and Chugoku Cancer Center
    Kure-shi, Hiroshima
    Site status: Not listed — confirm with the team
  • Goryokai Hospital
    Sapporo, Hokkaido
    Site status: Not listed — confirm with the team
  • Tatsuta Clinic
    Chuo-ku, Kobe-shi, Hyōgo
    Site status: Not listed — confirm with the team
  • Kishiro Mental Clinic
    Kawasaki-shi, Kanagawa
    Site status: Not listed — confirm with the team
  • Musashikosugi J Kokorono Clinic
    Kawasaki-shi, Kanagawa
    Site status: Not listed — confirm with the team
  • Hino Hospital
    Yokohama, Kanagawa
    Site status: Not listed — confirm with the team
  • Miki Mental Clinic
    Yokohama, Kanagawa
    Site status: Not listed — confirm with the team
  • Yamatenomori Kokorono Clinic
    Yokohama, Kanagawa
    Site status: Not listed — confirm with the team
  • Tosa Hospital
    Kochi, Kochi
    Site status: Not listed — confirm with the team
  • Kouyoudai Hospital
    Kumamoto, Kumamoto
    Site status: Not listed — confirm with the team
  • Satokai Yuge Hospital
    Kumamoto, Kumamoto
    Site status: Not listed — confirm with the team
  • Miyazaki Prefectural Miyazaki Hospital
    Miyazaki, Miyazaki
    Site status: Not listed — confirm with the team
  • Ozawa Mental Clinic
    Matsumoto-shi, Nagano
    Site status: Not listed — confirm with the team
  • Okayama Psychiatric Medical Center
    Okayama, Okayama-ken
    Site status: Not listed — confirm with the team
  • NHO Ryukyu Hospital
    Kunigami-gun, Okinawa
    Site status: Not listed — confirm with the team
  • Akari Clinic
    Naha, Okinawa
    Site status: Not listed — confirm with the team
  • Miebashi Clinic
    Naha, Okinawa
    Site status: Not listed — confirm with the team
  • Barclay Imuro Mental Clinic
    Urasoe-shi, Okinawa
    Site status: Not listed — confirm with the team
  • Shiroma Clinic
    Urasoe-shi, Okinawa
    Site status: Not listed — confirm with the team
  • Kansai Medical University Medical Center
    Moriguchi-shi, Osaka
    Site status: Not listed — confirm with the team
  • Keihan Hospital
    Moriguchi-shi, Osaka
    Site status: Not listed — confirm with the team
  • NHO Hizen Psychiatric Center
    Kanzaki-gun, Saga-ken
    Site status: Not listed — confirm with the team
  • Rainbow & Sea Hospital
    Karatsu-shi, Saga-ken
    Site status: Not listed — confirm with the team
  • Inuo Mental Care Hospital
    Tosu-shi, Saga-ken
    Site status: Not listed — confirm with the team
  • Nishi Kumagaya Hospital
    Kumagaya-shi, Saitama
    Site status: Not listed — confirm with the team
  • Mental Clinic Minami
    Saitama-shi, Saitama
    Site status: Not listed — confirm with the team
  • Ryokuwakai Stresscare Hibiya Clinic
    Chiyoda-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Murakami Hospital
    Edogawa-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Narimasu Kosei Hospital
    Itabashi-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Senzoku Psychosomatic Medicine Clinic
    Meguro-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Sakura-shinmachi Mental Clinic
    Setagaya-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Sangenjaya Neurology- Psychosomatic Clinic
    Setagaya-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Sangubashi Kokorono Clinic
    Shibuya-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Ohwa Mental Clinic
    Toshima-ku, Tokyo
    Site status: Not listed — confirm with the team
  • Sanyo Hospital
    Sakata-shi, Yamagata
    Site status: Not listed — confirm with the team
  • Yamagata Sakuracho Hospital
    Yamagata, Yamagata
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving SEP-363856. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Sumitomo Pharma Co., Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
TerminatedNCT04825860

SEP-363856 for schizophrenia

This study was terminated in China, in Japan, in the Philippines, .... It is testing SEP-363856 for schizophrenia.

Drug study icon
TerminatedNCT01125358

A Study in Schizophrenic Patients

This study has public registry information. It focuses on schizophrenia and currently lists study information in Japan, South Korea, and Taiwan.